The discovery of new leads acting via novel modes of action in the treatment of the human immunodeficiency virus (HIV), the causative agent of AIDS, remains a challenge. Along this line we synthesized and evaluated a series of N-substituted 4-aminophthalimides which were designed according to the models of thalidomide, phenytoin (PHT) and ameltolide. From a series of 24 compounds only N-1-adamantyl-4-aminophthalimide was endowed with anti-HIV-1 and -HIV-2 activity in CEM cell cultures.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0753-3322(97)82327-x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!